Typewriter secures $56M to advance jumping-gene platform and in vivo CAR-T therapies
read at Endpoints ↗DealPositive
Typewriter, a biotech startup, announced it has closed a $56 million financing round.
The capital will be used to develop its jumping-gene platform, which seeks to deliver full genes without viral vectors or CRISPR-based enzymes.
CEO Matthew Stanton and CSO Leanne Peiser said the funds will also support the advancement of in vivo CAR-T cell therapy programs.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapies”
read at Endpoints ↗89 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that